

Resource Summary Report

Generated by [dkNET](#) on Sep 3, 2026

A20

RRID:CVCL_1940

Type: Cell Line

Proper Citation

ATCC Cat# TIB-208, RRID:CVCL_1940

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1940

Proper Citation: ATCC Cat# TIB-208, RRID:CVCL_1940

Description: Cell line A20 is a Cancer cell line with a species of origin *Mus musculus* (Mouse)

Sex: Sex unspecified

Disease: Mouse reticulum cell sarcoma

Defining Citation: [PMID:310843](#), [PMID:22400032](#), [PMID:28902524](#), [PMID:31220119](#)

Comments: Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981)., Part of: ENCODE project mouse cell lines.

Category: Cancer cell line

Organism: *Mus musculus* (Mouse)

Name: A20

Synonyms: A-20

Cross References: BTO:BTO_0001930, CLO:CLO_0001564, CLO:CLO_0050194, EFO:EFO_0005285, ATCC:TIB-208, BCRC:60556, BCRJ:0030, BioSample:SAMN11397658, ChEMBL-Cells:ChEMBL3307765, ChEMBL-Targets:ChEMBL613850, CLS:305263, ENCODE:ENCBS119ENC, ENCODE:ENCBS431JNZ, GEO:GSM1014167, Lonza:743, PubChem_Cell_line:CVCL_1940, RCB:RCB2745, TKG:TKG 0571, TOKU-E:459, Ubigen:YC-C061, Wikidata:Q54606424

ID: CVCL_1940

Vendor: ATCC

Catalog Number: TIB-208

Record Creation Time: 20220427T215105+0000

Record Last Update: 20260830T001942+0000

Ratings and Alerts

No rating or validation information has been found for A20.

No alerts have been found for A20.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 42 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Liu S, et al. (2026) γ -hydroxybutyrate enhances the metabolic fitness of CAR T cells in cancer. *Cell*, 189(6), 1701.

García-Vicente R, et al. (2026) The Potential of the Gut Microbiota and Butyrate to Enhance CAR T-cell Therapy in Non-Hodgkin Lymphoma. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 32(2), 375.

Mao Y, et al. (2026) B cell deficiency limits exercise capacity by remodeling liver glutamate metabolism. *Cell*, 189(11), 3254.

Georgievski A, et al. (2026) Valrubicin-loaded immunoliposomes targeting antigens on immunosuppressive cells to circumvent resistance to cancer immunotherapy. *Cell reports. Medicine*, 7(3), 102632.

Wu L, et al. (2026) Controlled pyroptosis of engineered macrophages enables biphasic antitumor via the release of oncolytic bacteria and inflammatory signals. *Cell reports*, 45(2), 116918.

Hou L, et al. (2026) C-type lectin domain family 5 member A-mediated activation of macrophages via a bispecific antibody enhances anti-HER2 therapy. *Journal for immunotherapy of cancer*, 14(4).

Pizzo ME, et al. (2025) Transferrin receptor-targeted anti-amyloid antibody enhances brain delivery and mitigates ARIA. *Science (New York, N.Y.)*, 389(6760), eads3204.

Petkov V, et al. (2025) ISCOM-type matrix from beta-escin and glycyrrhizin saponins. *Heliyon*, 11(2), e41935.

Luo S, et al. (2025) TCL1A in naïve B cells as a therapeutic target for type 1 diabetes. *EBioMedicine*, 113, 105593.

Hesterberg RS, et al. (2025) Lymphoma accelerates T cell and tissue aging. *Cancer cell*.

Guruprasad P, et al. (2025) Manufacturing of CRISPR-edited primary mouse CAR T cells for cancer immunotherapy. *Nature protocols*.

Kim HY, et al. (2024) Specific targeting of cancer vaccines to antigen-presenting cells via an endogenous TLR2/6 ligand derived from cysteinyl-tRNA synthetase 1. *Molecular therapy : the journal of the American Society of Gene Therapy*, 32(10), 3597.

Xue G, et al. (2024) Clinical drug screening reveals clofazimine potentiates the efficacy while reducing the toxicity of anti-PD-1 and CTLA-4 immunotherapy. *Cancer cell*.

He MY, et al. (2024) GNAS knockout potentiates HDAC3 inhibition through viral mimicry-related interferon responses in lymphoma. *Leukemia*, 38(10), 2210.

Halász H, et al. (2024) Cooperation of Various Cytoskeletal Components Orchestrates Intercellular Spread of Mitochondria between B-Lymphoma Cells through Tunnelling Nanotubes. *Cells*, 13(7).

Yang Y, et al. (2024) The regulatory relationship between NAMPT and PD-L1 in cancer and identification of a dual-targeting inhibitor. *EMBO molecular medicine*, 16(4), 885.

Heiser RA, et al. (2024) Brentuximab Vedotin-Driven Microtubule Disruption Results in Endoplasmic Reticulum Stress Leading to Immunogenic Cell Death and Antitumor Immunity. *Molecular cancer therapeutics*, 23(1), 68.

Middelburg J, et al. (2023) The MHC-E peptide ligands for checkpoint CD94/NKG2A are governed by inflammatory signals, whereas LILRB1/2 receptors are peptide indifferent. *Cell reports*, 42(12), 113516.

Emrich SM, et al. (2023) Orai3 and Orai1 mediate CRAC channel function and metabolic reprogramming in B cells. *eLife*, 12.

Suzuki K, et al. (2023) Anti-PD-1 antibodies recognizing the membrane-proximal region are PD-1 agonists that can down-regulate inflammatory diseases. *Science immunology*, 8(79), eadd4947.